Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4Head & Neck 2Gastrointestinal 2Endocrine 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Lymphoid 1

Conditions

Liposarcoma 1

Interventions

Radiotherapy 216Cyclophosphamide 211Doxorubicin 207Temozolomide 181Ifosfamide 121Filgrastim 111Etoposide 101Imatinib Mesylate 99Vincristine 92Gemcitabine 89Bevacizumab 83Magnetic Resonance Spectroscopy 79Irinotecan 79pembrolizumab 75Radiation 67Carboplatin 65pazopanib 60Methotrexate 60Nivolumab 58Cisplatin 58fludarabine phosphate 56Peripheral Blood Stem Cell Transplantation 56Specimen Handling 53Docetaxel 50Busulfan 48Trabectedin 47Biopsy 47Melphalan 46Surgical Procedures, Operative 45Paclitaxel 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × efatutazone × Sarcoma × Clear all
NCT02249949 2025-01-27

Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery

Alliance for Clinical Trials in Oncology

Phase 2 Completed
15 enrolled 12 charts
Sarcoma

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡